{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:19:07Z","timestamp":1793143147962,"version":"4.5.0"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Anesthesia"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jclinane.2025.112064","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:21:22Z","timestamp":1761960082000},"page":"112064","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Pharmacogenetics in perioperative care: Understanding the impact of genetic variants on patient management"],"prefix":"10.1016","volume":"108","author":[{"given":"Jan Albert Nicolaas","family":"Groot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankie Maxelante","family":"Harmsze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Hendricus Paulus Adrianus","family":"van Dongen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherijne Anette Jantine","family":"Knibbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena Johanna Bluss\u00e9","family":"van Oud-Alblas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.jclinane.2025.112064_bb0005","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1001\/jama.286.18.2270","article-title":"Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review","volume":"286","author":"Phillips","year":"2001","journal-title":"Jama"},{"issue":"5","key":"10.1016\/j.jclinane.2025.112064_bb0010","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1213\/ANE.0000000000005951","article-title":"Pilot findings of pharmacogenomics in perioperative care: initial results from the first phase of the ImPreSS trial","volume":"135","author":"Truong","year":"2022","journal-title":"Anesth Analg"},{"key":"10.1016\/j.jclinane.2025.112064_bb0015","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00019053-200321090-00002","article-title":"Assessing the economic impact of adverse drug effects","volume":"21","author":"Rodr\u00edguez-Mongui\u00f3","year":"2003","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.jclinane.2025.112064_bb0020","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(02)11203-7","article-title":"Clinical importance of the cytochromes P450","volume":"360","author":"Nebert","year":"2002","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jclinane.2025.112064_bb0025","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jclinane.2025.112064_bb0030","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/bja\/88.5.653","article-title":"Propofol metabolites in man following propofol induction and maintenance","volume":"88","author":"Favetta","year":"2002","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.jclinane.2025.112064_bb0035","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1038\/s41598-017-03229-3","article-title":"Association of polymorphisms in pharmacogenetic candidate genes with propofol susceptibility","volume":"7","author":"Zhong","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jclinane.2025.112064_bb0040","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/01.fpc.0000114754.08559.27","article-title":"Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver","volume":"14","author":"Girard","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.jclinane.2025.112064_bb0045","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/bcpt.12277","article-title":"Pharmacogenetics, plasma concentrations, clinical signs and EEG during propofol treatment","volume":"115","author":"Khan","year":"2014","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.jclinane.2025.112064_bb0050","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/cpt.2350","article-title":"An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine","volume":"110","author":"Whirl-Carrillo","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jclinane.2025.112064_bb0055","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2133\/dmpk.DMPK-13-NT-092","article-title":"Association of the CYP2B6 c.516G>T polymorphism with high blood Propofol concentrations in women from northern Greece","volume":"29","author":"Mastrogianni","year":"2014","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.jclinane.2025.112064_bb0060","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s13318-015-0289-y","article-title":"Impact of the cytochrome P450 2B6 (CYP2B6) gene polymorphism c.516G>T (Rs3745274) on Propofol dose variability","volume":"41","author":"Mour\u00e3o","year":"2016","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.jclinane.2025.112064_bb0065","first-page":"109","article-title":"A single nucleotide polymorphism-based formula to predict the risk of Propofol TCI concentration being over 4 \u039cg mL(\u22121) at the time of loss of consciousness","volume":"22","author":"Zheng","year":"2022","journal-title":"Pharm J"},{"key":"10.1016\/j.jclinane.2025.112064_bb0070","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/sj.clpt.6100095","article-title":"Pharmacogenetics of opioids","volume":"81","author":"Somogyi","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jclinane.2025.112064_bb0075","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/bcpt.13141","article-title":"Polymorphisms associated with fentanyl pharmacokinetics, pharmacodynamics and adverse effects","volume":"124","author":"Saiz-Rodr\u00edguez","year":"2019","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.jclinane.2025.112064_bb0080","doi-asserted-by":"crossref","first-page":"414","DOI":"10.2133\/dmpk.DMPK-11-RG-134","article-title":"Impact of CYP3A5 and ABCB1 gene polymorphisms on fentanyl pharmacokinetics and clinical responses in Cancer patients undergoing conversion to a transdermal system","volume":"27","author":"Takashina","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.jclinane.2025.112064_bb0085","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/FPC.0000000000000032","article-title":"Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 Cancer patients of the EPOS study","volume":"24","author":"Barratt","year":"2014","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jclinane.2025.112064_bb0090","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/sj.clpt.6100046","article-title":"Genetic polymorphisms in the ABCB1 gene and the effects of fentanyl in Koreans","volume":"81","author":"Park","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jclinane.2025.112064_bb0095","first-page":"119","article-title":"Opioid-induced respiratory depression: ABCB1 transporter pharmacogenetics","volume":"15","author":"Sadhasivam","year":"2015","journal-title":"Pharm J"},{"key":"10.1016\/j.jclinane.2025.112064_bb0100","first-page":"154","article-title":"ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research","volume":"7","author":"Leschziner","year":"2007","journal-title":"Pharm J"},{"key":"10.1016\/j.jclinane.2025.112064_bb0105","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1177\/147323001204000204","article-title":"Signal transduction pathways and transcriptional mechanisms of ABCB1\/Pgp-mediated multiple drug resistance in human Cancer cells","volume":"40","author":"Sui","year":"2012","journal-title":"J Int Med Res"},{"key":"10.1016\/j.jclinane.2025.112064_bb0110","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.neuroscience.2009.10.011","article-title":"Evidence that intrathecal Morphine-3-glucuronide may cause pain enhancement via toll-like receptor 4\/MD-2 and interleukin-1beta","volume":"165","author":"Lewis","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.jclinane.2025.112064_bb0115","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/1742-2094-9-200","article-title":"Neuroexcitatory effects of Morphine-3-glucuronide are dependent on toll-like receptor 4 signaling","volume":"9","author":"Due","year":"2012","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.jclinane.2025.112064_bb0120","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0009-9236(03)00053-5","article-title":"A Pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine","volume":"73","author":"Sawyer","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jclinane.2025.112064_bb0125","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.bcp.2013.06.019","article-title":"Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration","volume":"86","author":"Tzvetkov","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jclinane.2025.112064_bb0130","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2217\/pgs-2017-0002","article-title":"OCT1 genetic variants are associated with postoperative morphine-related adverse effects in children","volume":"18","author":"Balyan","year":"2017","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jclinane.2025.112064_bb0135","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.2217\/pgs.13.94","article-title":"OCT1 genetic variants influence the pharmacokinetics of morphine in children","volume":"14","author":"Fukuda","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jclinane.2025.112064_bb0140","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/bcpt.13667","article-title":"No significant influence of OCT1 genotypes on the pharmacokinetics of morphine in adult surgical patients","volume":"130","author":"Kuhlmann","year":"2022","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.jclinane.2025.112064_bb0145","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41398-020-01129-1","article-title":"Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19","volume":"11","author":"Koopmans","year":"2021","journal-title":"Transl Psychiatry"},{"issue":"3","key":"10.1016\/j.jclinane.2025.112064_bb0150","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.amjms.2018.11.002","article-title":"Pseudocholinesterase deficiency: what the proceduralist needs to know","volume":"357","author":"Robles","year":"2019","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jclinane.2025.112064_bb0155","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/s41431-021-00920-y","article-title":"Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone)","volume":"30","author":"Matic","year":"2022","journal-title":"Eur J Human Genet EJHG"},{"key":"10.1016\/j.jclinane.2025.112064_bb0160","first-page":"257","article-title":"Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers Due to CYP2D6 duplication","volume":"7","author":"Kirchheiner","year":"2007","journal-title":"Pharm J"},{"key":"10.1016\/j.jclinane.2025.112064_bb0165","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/JCP.0b013e318160f827","article-title":"Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol","volume":"28","author":"Kirchheiner","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.jclinane.2025.112064_bb0170","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13091466","article-title":"Contribution of CYP2D6 functional activity to oxycodone efficacy in pain management: genetic polymorphisms, Phenoconversion, and tissue-selective metabolism","volume":"13","author":"Deodhar","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jclinane.2025.112064_bb0175","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.clpt.2006.01.009","article-title":"Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites","volume":"79","author":"Lalovic","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jclinane.2025.112064_bb0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060239","article-title":"CYP2D6 genotype dependent oxycodone metabolism in postoperative patients","volume":"8","author":"Stamer","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jclinane.2025.112064_bb0185","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1399-6576.2009.02104.x","article-title":"Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia","volume":"54","author":"Zwisler","year":"2010","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.jclinane.2025.112064_bb0190","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1476-5381.2010.00709.x","article-title":"Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety","volume":"160","author":"Samer","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jclinane.2025.112064_bb0195","article-title":"Cytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting","volume":"11","author":"Janicki","year":"2005","journal-title":"Med Sci Monitor: Int Med J Exp Clin Res"},{"key":"10.1016\/j.jclinane.2025.112064_bb0200","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1213\/ANE.0b013e31821d01bc","article-title":"CYP2D6- and CYP3A-dependent enantioselective plasma concentrations of ondansetron in Postanesthesia care","volume":"113","author":"Stamer","year":"2011","journal-title":"Anesth Analg"},{"key":"10.1016\/j.jclinane.2025.112064_bb0205","first-page":"153","article-title":"Effects of (RS)-ondansetron and its enantiomers on QTc interval in rats","volume":"3","author":"Bodhankar","year":"2006","journal-title":"Pharmacologyonline"},{"key":"10.1016\/j.jclinane.2025.112064_bb0210","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/00000542-200503000-00011","article-title":"The impact of pharmacogenomics on postoperative nausea and vomiting: do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis?","volume":"102","author":"Candiotti","year":"2005","journal-title":"Anesthesiology"},{"key":"10.1016\/j.jclinane.2025.112064_bb0215","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1213\/01.ane.0000200364.55798.3f","article-title":"Prevention of postoperative nausea and vomiting with granisetron and dolasetron in relation to CYP2D6 genotype","volume":"102","author":"Janicki","year":"2006","journal-title":"Anesth Analg"},{"key":"10.1016\/j.jclinane.2025.112064_bb0220","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/cpt.598","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and Tropisetron","volume":"102","author":"Bell","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jclinane.2025.112064_bb0225","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/PGPM.S348170","article-title":"GABRA1 and GABRB2 polymorphisms are associated with propofol susceptibility","volume":"15","author":"Zeng","year":"2022","journal-title":"Pharmacogenom Personalized Med"},{"key":"10.1016\/j.jclinane.2025.112064_bb0230","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1177\/0300060515587580","article-title":"Polymorphism Rs4263535 in GABRA1 intron 4 was related to deeper sedation by intravenous midazolam","volume":"43","author":"Choi","year":"2015","journal-title":"J Int Med Res"},{"key":"10.1016\/j.jclinane.2025.112064_bb0235","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/bcp.15480","article-title":"Nongenetic and genetic predictors of haemodynamic instability induced by Propofol and opioids: a retrospective clinical study","volume":"89","author":"Gu","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jclinane.2025.112064_bb0240","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0014-2999(00)00819-0","article-title":"Opioid receptor and peptide gene polymorphisms: potential implications for addictions","volume":"410","author":"LaForge","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jclinane.2025.112064_bb0245","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/ALN.0b013e318182af21","article-title":"A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia","volume":"109","author":"Sia","year":"2008","journal-title":"Anesthesiology"},{"key":"10.1016\/j.jclinane.2025.112064_bb0250","doi-asserted-by":"crossref","first-page":"32618","DOI":"10.1074\/jbc.M504942200","article-title":"Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G","volume":"280","author":"Zhang","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jclinane.2025.112064_bb0255","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jpain.2004.11.008","article-title":"The A118G single nucleotide polymorphism of the mu-opioid receptor gene (OPRM1) is associated with pressure pain sensitivity in humans","volume":"6","author":"Fillingim","year":"2005","journal-title":"J Pain"},{"key":"10.1016\/j.jclinane.2025.112064_bb0260","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3346\/jkms.2015.30.5.651","article-title":"Effects of \u039c-opioid receptor gene polymorphism on postoperative nausea and vomiting in patients undergoing general anesthesia with remifentanil: double blinded randomized trial","volume":"30","author":"Lee","year":"2015","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.jclinane.2025.112064_bb0265","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1007\/s00221-014-3987-9","article-title":"Association of \u03bc-opioid receptor gene (OPRM1) haplotypes with postoperative nausea and vomiting","volume":"232","author":"Sugino","year":"2014","journal-title":"Exp Brain Res"},{"key":"10.1016\/j.jclinane.2025.112064_bb0270","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/npp.2014.272","article-title":"Effects of the mu opioid receptor polymorphism (OPRM1 A118G) on pain regulation, placebo effects and associated personality trait measures","volume":"40","author":"Peci\u00f1a","year":"2015","journal-title":"Neuropsychopharmacol Offl Publ Am College Neuropsychopharmacol"},{"key":"10.1016\/j.jclinane.2025.112064_bb0275","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/ALN.0000000000000405","article-title":"OPRM1 A118G gene variant and postoperative opioid requirement: a systematic review and meta-analysis","volume":"121","author":"Hwang","year":"2014","journal-title":"Anesthesiology"},{"key":"10.1016\/j.jclinane.2025.112064_bb0280","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ajmg.b.32556","article-title":"Association between COMT Val158Met and psychiatric disorders: A comprehensive meta-analysis","volume":"177","author":"Taylor","year":"2018","journal-title":"Am J Med Genet Part B, Neuropsychiatric Genet Offl Publ Int Soc Psychiatric Genet"},{"key":"10.1016\/j.jclinane.2025.112064_bb0285","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1523\/JNEUROSCI.0774-07.2007","article-title":"Catechol O-methyltransferase Val158Met genotype influences Frontoparietal activity during planning in patients with Parkinson\u2019s disease","volume":"27","author":"Williams-Gray","year":"2007","journal-title":"J Neurosci"},{"key":"10.1016\/j.jclinane.2025.112064_bb0290","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00008571-199606000-00007","article-title":"Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders","volume":"6","author":"Lachman","year":"1996","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.jclinane.2025.112064_bb0295","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1021\/bi00013a008","article-title":"Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the Thermolabile variant of the enzyme","volume":"34","author":"Lotta","year":"1995","journal-title":"Biochemistry"},{"key":"10.1016\/j.jclinane.2025.112064_bb0300","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1126\/science.1078546","article-title":"COMT Val158met Genotype Affects Mu-Opioid Neurotransmitter Responses to a Pain Stressor","volume":"299","author":"Zubieta","year":"2003","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.jclinane.2025.112064_bb0305","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1213\/ANE.0b013e318202cc8d","article-title":"Combined catechol-O-methyltransferase and mu-opioid receptor gene polymorphisms affect morphine postoperative analgesia and central side effects","volume":"112","author":"Kolesnikov","year":"2011","journal-title":"Anesth Analg"},{"key":"10.1016\/j.jclinane.2025.112064_bb0310","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.pain.2005.03.032","article-title":"The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients","volume":"116","author":"Rakv\u00e5g","year":"2005","journal-title":"Pain"},{"key":"10.1016\/j.jclinane.2025.112064_bb0315","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/bcp.12052","article-title":"The Val158Met polymorphism of the COMT gene is associated with increased pain sensitivity in morphine-treated patients undergoing a painful procedure after cardiac surgery","volume":"75","author":"Ahlers","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jclinane.2025.112064_bb0320","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2217\/pgs-2019-0141","article-title":"OPRM1 and COMT polymorphisms: implications on postoperative acute, chronic and experimental pain after cardiac surgery","volume":"21","author":"Matic","year":"2020","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jclinane.2025.112064_bb0325","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0006016","article-title":"Increased sensitivity to thermal pain following a single opiate dose is influenced by the COMT Val(158)met polymorphism","volume":"4","author":"Jensen","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.jclinane.2025.112064_bb0330","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1136\/jmg.2004.027698","article-title":"Melanocortin-1 receptor gene variants affect pain and mu-opioid analgesia in mice and humans","volume":"42","author":"Mogil","year":"2005","journal-title":"J Med Genet"},{"key":"10.1016\/j.jclinane.2025.112064_bb0335","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00000542-200408000-00006","article-title":"Anesthetic requirement is increased in redheads","volume":"101","author":"Liem","year":"2004","journal-title":"Anesthesiology"},{"key":"10.1016\/j.jclinane.2025.112064_bb0340","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd1310","article-title":"Reduced MC4R signaling alters nociceptive thresholds associated with red hair","volume":"7","author":"Robinson","year":"2021","journal-title":"Sci Adv"},{"issue":"2","key":"10.1016\/j.jclinane.2025.112064_bb0345","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s44254-023-00017-3","article-title":"Red hair and pain sensitivity: insights into genomics of pain?","volume":"1","author":"Williams","year":"2023","journal-title":"Anesthesiol Perioper Sci"},{"key":"10.1016\/j.jclinane.2025.112064_bb0350","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.pharmthera.2014.11.011","article-title":"Review of human Butyrylcholinesterase structure, function, genetic variants, history of use in the clinic, and potential therapeutic uses","volume":"148","author":"Lockridge","year":"2015","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jclinane.2025.112064_bb0355","first-page":"700","article-title":"Incidence of malignant hyperthermia in Denmark","volume":"64","author":"Ording","year":"1985","journal-title":"Anesth Analg"},{"key":"10.1016\/j.jclinane.2025.112064_bb0360","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13023-015-0310-1","article-title":"Malignant hyperthermia: a review","volume":"10","author":"Rosenberg","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jclinane.2025.112064_bb0365","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/sj.ejhg.5200964","article-title":"Recent advances in the diagnosis of malignant hyperthermia susceptibility: how confident can we be of genetic testing?","volume":"11","author":"Robinson","year":"2003","journal-title":"Eur J Human Genet EJHG"},{"key":"10.1016\/j.jclinane.2025.112064_bb0370","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1471-2350-10-104","article-title":"The role of CACNA1S in predisposition to malignant hyperthermia","volume":"10","author":"Carpenter","year":"2009","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.jclinane.2025.112064_bb0375","author":"European Malignant Hyperthermia Group"},{"issue":"2","key":"10.1016\/j.jclinane.2025.112064_bb0380","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1152\/physiolgenomics.00126.2016","article-title":"Pharmacogenetics and pathophysiology of CACNA1S mutations in malignant hyperthermia","volume":"49","author":"Beam","year":"2017","journal-title":"Physiol Genomics"},{"issue":"10","key":"10.1016\/j.jclinane.2025.112064_bb0385","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/humu.20356","article-title":"Mutations in RYR1 in malignant hyperthermia and central core disease","volume":"27","author":"Robinson","year":"2006","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jclinane.2025.112064_bb0390","author":"U.S. Food and Drug Administration"},{"key":"10.1016\/j.jclinane.2025.112064_bb0395","author":"Clinical Pharmacogenetics Implementation Consortium"},{"key":"10.1016\/j.jclinane.2025.112064_bb0400","author":"Dutch Pharmacogenetics Working Group"}],"container-title":["Journal of Clinical Anesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952818025003253?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952818025003253?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T20:23:13Z","timestamp":1768854193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952818025003253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":80,"alternative-id":["S0952818025003253"],"URL":"https:\/\/doi.org\/10.1016\/j.jclinane.2025.112064","relation":{},"ISSN":["0952-8180"],"issn-type":[{"value":"0952-8180","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacogenetics in perioperative care: Understanding the impact of genetic variants on patient management","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Anesthesia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jclinane.2025.112064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112064"}}